Genetic evidence indicated that individuals with inactivating mutations in PCSK9 have decreased levels of circulating LDL and CAD risk, which led to the two monoclonal antibodies that inhibit PCSK9 to be approved by the United States Food and Drug Administration (Cohen et al., 2006). Here, PCSK9 is linked to coronary artery disorder.